The latest announcement is out from ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ).
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has announced a board meeting scheduled for March 25, 2025, to discuss and approve the company’s annual results for the year ending December 31, 2024, and to consider recommending a final dividend. This meeting is significant for stakeholders as it will provide insights into the company’s financial health and potential returns, impacting its market positioning.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biopharmaceutical company based in China, focusing on the development of innovative cancer immunotherapies.
YTD Price Performance: -3.29%
Average Trading Volume: 9,316,523
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$1.98B
For an in-depth examination of 1541 stock, go to TipRanks’ Stock Analysis page.